$ARWR the sp has changed...the story has not 3 pivotal trials in 2020....data on ang3 and apoc3 expected first in lung with enac sometime in 2020 hsd and hif2 trials to begin amg890 to file for phase 2 with a phase one data dump and a milestone payment jnj3989 continues a robust phase 2 trial off of incredible phase one data jnj could/should accept option for jnj2 & jnj3 and also reveal target for jnj1 & the curtain rises on a muscle target this year all while management prepares for commercialization throw in a wildcard or two for good measure 10 drugs in 2020 20 in 2022 the sp will catch up to the story/data....patience/persistence
  • 21
  • 1